

### Company Overview

Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company's core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company's PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations.

The company's product pipeline includes CLR 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope) directly to cancer cells, while limiting exposure to healthy cells unlike many traditional on-market treatment options. CLR 131, is currently in a clinical study for hematologic malignancies and a pediatric safety study, one preclinical PDC chemotherapeutic program (CLR 1900) and multiple partnered PDC assets.

For more information, please visit [www.cellectar.com](http://www.cellectar.com) or join the conversation by liking and following us on the company's social media channels: [Twitter](#), [LinkedIn](#), and [Facebook](#).

### Cellectar Strengthens Global IP Position with Phospholipid Drug Conjugate Composition of Matter Patent in Eurasia, Australia, and Mexico

Apr 27 2021, 8:39 AM EDT

### Cellectar to Participate at Upcoming Institutional Investor Conferences

Mar 11 2021, 8:30 AM EST

### Cellectar Granted Japanese Composition of Matter Patent for its Phospholipid-Ether Drug Conjugates

Mar 9 2021, 9:00 AM EST

### Stock Overview

Symbol	CLRB
Exchange	Nasdaq
Market Cap	71.71m
Last Price	\$1.36
52-Week	\$1.01 - \$2.99

05/07/2021 04:00 PM EDT

### Investor Relations

LifeSci Advisors
Monique Kosse
Managing Director
T: 212-915-3820
<a href="mailto:monique@lifesciadvisors.com">monique@lifesciadvisors.com</a>

### Management Team

#### James Caruso

President, CEO and Director

#### Dov Elefant

Vice President and Chief Financial Officer

#### Dr. John Friend

Chief Medical Officer

#### Jarrod Longcor

Chief Business Officer

### Cellectar Biosciences, Inc.

100 Campus Drive, Suite 207  
 Florham Park, NJ 07932

### Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.

